Purchase this article with an account.
C.-C. Lai, K.-J. Chen, Y.-S. Hwang, J.-C. Kuo, N.-K. Wang, W.-C. Wu, L. Yeung, L.-H. Chuang; Chronic Central Serous Chorioretinopathy Treated by 1/3 Dose of Verteporfin Photodynamic Therapy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):750.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the use of 1/3 dosage of verteporfin photodynamic therapy (PDT) to treat patients with chronic central serous chorioretinopathy (CSC).
Twenty-one eyes of 21 patients with symptomatic chronic CSC underwentindocyanine green angiography (ICG)-guided PDT with 1/3 dose verteporfin were reviewed. The standard PDT procedure was performed except only 1/3 dose verteporfin was given to patient. Outcome measures included logMAR best-corrected visual acuity (BCVA), central retinal thickness, and angiographic changes during the study period.
Neurosensory detachment and fluorescein leakage resolved in 20 patients within 1 month. All (21 eyes) subretinal fluid was resolved on 3 months after PDT. There was a statistically significant improvement in mean VA (P < 0.05, Wilcoxon signed ranks test), and mean VA improved from 20/80 to 20/40. No patient lost vision or suffered any treatment-related complications.
The treatment of chronic CSC with 1/3 dosage of verteporfin PDT may result in prompt resolution of neurosensory detachment and fluorescein leakage, which can be associated with rapidly improved vision. The encouraging results and lack of visually significant complications suggest that further investigation is warranted.
This PDF is available to Subscribers Only